United States · 
What does Signet Healthcare Partners invest in?
Signet Healthcare Partners invests most often at Series A and Series B (60% of the rounds on record), in sectors such as Longevity, Healthier Living and Connected-health.
Signet Healthcare Partners highlights
- 01
10 rounds on record
- 02
Mostly Series A and Series B: 60% of its rounds
- 03
Sole investor in 2 rounds, median $14M
- 04
3 exits from the portfolio
What they do
Signet Healthcare Partners is a leading provider of growth capital to innovative healthcare companies around the world.From their own website
- Type
- VC firm (from a list, unverified)
- Cheque size
- Not stated
- Stages
- SeedSeries ASeries BGrowth
- Sectors
- LongevityHealthier LivingConnected-health
- Based in
- New York, United States
- Cold pitches
- Not stated
The record
Every round we can evidence, newest first10 appearances
- 2015
1 round
- Jul
- 2014
2 rounds
- Dec
- Jul
- 2010
1 round
- Nov
- 2009
1 round
- Dec
- 2008
2 rounds
- Aug
- Feb
- 2007
2 rounds
- Oct
- Aug
- 2004
1 round
- Mar
An announcement gives the size of the round, not the size of this investor's cheque: the only rounds that imply a cheque are those where they were the sole named investor.
The team
Named by the firm itself, on a filing, its Form ADV or its company registration3 named
ACAshley C. FriedmanExecutive OfficeriFiling they signed
JCJames Charles GaleExecutive Officer, DirectoriFiling they signed
NCNikhil C. PuriExecutive OfficeriFiling they signed
We also hold 7 people at this firm from the lists this database was built from: a weaker source than the filings, since a list does not say when a title ended. Login to see them.
What the register says
From the firm's own filings with the SEC, which it must file accurately by law
$239Mgross assets of its fundsOct 2026
Exemptreporting adviserventure or small private funds
- Legal name
- Signet Healthcare Management LLC
- SEC number
- CRD 284087
What they claim to have backed
From their own portfolio page (on their website)
11 of 52 we have independently watched raise
ArgostherapeuticsBionpharmaIconbioscienceLeadingpharmaLeon-nanodrugsOctoplusParagonixtechnologiesPharm-intPrimrosebioSpepharmTelabioAdvanticehealthAltasciencesAmarincorpAmriglobalAnteisApicoreArborpharmaAscendiapharmaAvantiumBiojectCangeneChr-olesenClarislifesciencesCorerxpharmaCuridaDirevoElanEndoErtFluxionbioGbibioGi-supplyImpopharmaJunopharmKewincLaxaiLigandMalladiMallinckrodtMedtronicMolecularmedNxbioOptiscancorpPainteqPharmanobisRkpharmaincSancilioSmartmedsysTeambestTeligentVigenebio
Weaker than a round we watched, stronger than a list somebody sold us. A firm is far less willing to put a company on its own site that it never funded.
Exits from the portfolio
Companies it backed that were later bought or listed3 in all
Cedarburg Hauser PharmaceuticalsBought by Albany Molecular Research$41MMar 2014
PEAK SurgicalBought by Medtronic$120MJul 2011
DIREVO Industrial BiotechnologyBought by Bayer HealthCare$297MSept 2008
An exit counts when it came after the firm's first round in the company. From historical deal records.